Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May;28(3):733-744.
doi: 10.1007/s10741-021-10157-y. Epub 2021 Aug 11.

Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients

Michele Correale  1 , Olga Lamacchia  2 , Michele Ciccarelli  3 , Giuseppe Dattilo  4 , Lucia Tricarico  2 , Natale Daniele Brunetti  2
Affiliations
Review

Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients

Michele Correale et al. Heart Fail Rev. 2023 May.

Abstract

Alterations of endothelial function, inflammatory activation, and nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway are involved in the pathophysiology of heart failure. Metabolic alterations have been studied in the myocardium of heart failure (HF) patients; alterations in ketone body and amino acid/protein metabolism have been described in patients affected by HF, as well as mitochondrial dysfunction and other modified metabolic signaling. However, their possible contributions toward cardiac function impairment in HF patients are not completely known. Recently, sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have emerged as a new class of drugs designed to treat patients with type 2 diabetes (T2D), but have also been shown to be protective against HF-related events and CV mortality. To date, the protective cardiovascular effects of these drugs in patients with and without T2D are not completely understood and several mechanisms have been proposed. In this review, we discuss on vascular and metabolic effects of SGLT2i and GLP-1 in HF patients.

Keywords: Endothelial function; GLP-1 RA; Gliflozin; Heart failure; Metabolic effect; SGLT2i.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Correale M, Leopizzi A, Mallardi A, Ranieri A, Suriano MP, D’Alessandro D, Tricarico L, Mazzeo P, Tucci S, Pastore G, Maulucci G, Di Biase M, Brunetti ND (2020) Switch to direct anticoagulants and improved endothelial function in patients with chronic heart failure and atrial fibrillation. Thromb Res 195:16–20 - PubMed - DOI
    1. Zuchi C, Tritto I, Carluccio E, Mattei C, Cattadori G, Ambrosio G (2020) Role of endothelial dysfunction in heart failure. Heart Fail Rev 25:21–30 - PubMed - DOI
    1. Giannitsi S, Bougiakli M, Bechlioulis A, Naka K (2019) Endothelial dysfunction and heart failure: A review of the existing bibliography with emphasis on flow mediated dilation. JRSM Cardiovasc Dis 11(8):2048004019843047
    1. Correale M, Paolillo S, Mercurio V, Limongelli G, Barillà F, Ruocco G, Palazzuoli A, Scrutinio D, Lagioia R, Lombardi C, Lupi L, Magrì D, Masarone D, Pacileo G, Scicchitano P, Matteo Ciccone M, Parati G, Tocchetti CG, Nodari S (2020) Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure. Eur J Intern Med 71:23–31 - PubMed - DOI
    1. Yazaki Y, Isobe M, Takahashi W, Kitabayashi H, Nishiyama O, Sekiguchi M, Takemura T (1999) Assessment of myocardial fatty acid metabolic abnormalities in patients with idiopathic dilated cardiomyopathy using 123I BMIPP SPECT: correlation with clinicopathological findings and clinical course. Heart 81:153–159 - PubMed - PMC - DOI

MeSH terms

Substances

LinkOut - more resources

  NODES
INTERN 1
Project 1
twitter 2